A multicentered, double blind, Randomized, parallel group, placebo controlled, prospective study to evaluate efficacy and safety of Shred Nâ?? Fit in Obese Subjects. - SNF

Gangwal Healthcare Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月1日

试验速览

暂无简介。

•1.Male and/or female volunteers aged between >=18 to 65>= years.
•2.Subjects with BMI >= 25Kg/m2 and 34.9>= kg/m2.
•3.Subjects who are willing to do exercise for a span of 30 minutes daily for at least 5 days in a week.
•4.Subjects who are willing to follow diet advised by investigator.
•5.Subjects who are willing to give Inform consent.
•6.Subjects who are willing to come for regular follow-up visits.

•1.Subjects having intake of over-the-counter weight loss agents, centrally acting appetite suppressants or prior surgery for obesity in the previous three months or planning to undergo such surgery within 2 months.
•2.History of pathophysiologic/genetic syndromes associated with obesity (Cushingâ??s syndrome, Turnerâ??s syndrome, and Parder- Willi Syndrome).
•3.Alcoholics and subjects with substance abuse.
•4.Subject with evidence of malignancy.
•5.Subjects having history of underlying inflammatory arthropathy, septic arthritis, inflammatory joint disease, gout, pseudo gout, Pagetâ??s disease, joint fracture, acromegaly, fibromyalgia, rheumatoid arthritis.
•6.Subjects having history of coagulopathies, cardiovascular diseases, asthma.
•7.Pregnant and lactating women.
•8.Subjects with hepatic and renal failure.
•9.Subjects on prolonged ( > 6 weeks) medication with corticosteroids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.
•10.Subjects with hypersensitivity to any one ingredient of the drugs.
•11.Subjects who have participated in other trial within last 3 months.
•12.Any other condition which the principal investigator thinks may jeopardize the study.

发起方

Gangwal Healthcare Pvt Ltd